---

SAN JOSE, Calif.--(BUSINESS WIRE)--Starch Medical Inc. a privately held manufacturer and marketer of polysaccharide based hemostatic products for use in controlling bleeding in surgery and trauma applications has expanded its product portfolio with the launch of SuperClot ® Hemostat in Europe.Starch Medical received CE Approval earlier this year for SuperClot ® and will utilize their existing network of distribution partners along with new strategic partners to bring this innovative new polymer hemostat solution to surgical teams and hospitals throughout Europe. Next week Starch Medical will exhibit and hold distributor meetings at MEDICA the world ' s leading trade fair for the medical industry held in D üsseldorf, Germany from November 13-16, 2017.“The market for economical, safe and effective polysaccharide hemostats is growing rapidly worldwide and especially in Europe. Our exclusive agreement to market Starch Medical’s SuperClot® Hemostat in Italy provides us with the opportunity to better serve our hospitals and their patients,” sa id Giovanni Capello, Chief Executive Officer of Medix. “In addition to rapid and effective hemostasis, our surgeons are attracted by the wide variety of surgical applications where SuperClot® can be used. We believe that Starch Medical’s hemostat product line including SealFoam®, SealFoam® St ernal and now SuperClot® will become the standard to control the majority of surgical bleeding in the future.”“Surgeons and hospit...
Source: Medical Hemostat - Category: Medical Devices Authors: Source Type: blogs